Pharma’s Physician Bailout
The pharmaceutical industry has been very generous in making payments to physicians. Last year (2010), for example, a mere dozen pharmaceutical companies paid $760 million to physicians and other health care providers for consulting, speaking, research and expenses. On average, how much do you think that comes to for every physician in the U.S.?
Pharma Marketing News Vol. 10, No. 10: 8 June 2011
Welcome to Volume 10, Issue #10 (8 JUNE 2011) of Pharma Marketing News.
Pharma Marketing News Vol. 10, No. 15: 12 October 2011
Welcome to Volume 10, Issue #15 (12 OCTOBER 2011) of Pharma Marketing News.
Politics Vs. Science in the Plan B Decision
Sebelius focused on the fact that Teva's study did not contain data for all ages for which this product would be available for use. According to Tina Raine-Bennett, MD, MPH, of the Women's Health Research Institute at Kaiser Permanente Northern California, a principal investigator of the University of California-San Francisco study, it is unreasonable and virtually impossible to study the use of emergency contraception in 11- and 12-year-olds, because only a small fraction of them will have had sex by that age.
Antidepressants: Top Advertised & 3rd Most Commonly Used Rx Drug
According to a recent CDC Data Brief, antidepressants were the third most common prescription drug taken by Americans of all ages in 2005–2008 and the most frequently used by persons aged 18–44 years. From 1988–1994 through 2005–2008, the rate of antidepressant use in the United States among all ages increased nearly 400%. Perhaps not so coincidentally, antidepressants are among the TOP advertised Rx category in 2010, according to the recent AdAge analysis.
Are Sales Reps as “Useful” as PhRMA Wants Us to Believe?
Let's Look at Some Data PhRMA Doesn't Mention. PhRMA pointed out that nearly 9 out of 10 physicians considered company-sponsored peer education programs to be 'up-to-date, useful and reliable.'
Orphan Drugs Now “Where the Money Is,” Says Willie Sutton’s Ghost
Why do pharma companies bother developing drugs for for a disorder affecting fewer than 200,000 people? Willie Sutton's ghost may have the answer.
The Changing Role of Pharma Sales Reps
Pharma companies need to drive maximum value out of products and they can't do that with a 'one-size-fits-all' cookie-cutter approach to deploying field forces. Brand managers will look to outsourced providers to take advantage of the expertise these providers can bring to the table. This article is a summary of an interview of Nancy Lurker, CEO of PDI, Inc., which provides promotional outsourced services to healthcare companies.
Certain Physician-Drug Industry Relationships Have Declined Dramatically
The authors of a physician survey published in the November 8, 2010, issue of Archives of Internal Medicine conclude 'given that 83.8% of physicians have PIRs, it is clear that industry still has substantial financial links with the nation's physicians. These findings support the ongoing need for a national system of disclosure of PIRs [Physician-Drug Industry Relationships].' Such a system is part of the Physician Sunshine Law, which is scheduled to go into effect in 2012 with public disclosure of payments scheduled to begin September, 2013.
Pfizer Battles to Protect Lipitor Cash Cow
Lipitor Won't Go Gentle Into that Good Generic Night. Pfizer is taking a number of steps to protect it's Lipitor franchise and it hopes that many patients currently taking Lipitor will remain loyal to the brand.
